Williams v Quest/Athena struck a nerve with the genetic testing community by probing what the standard of care is and ought to be for variant classification.
The company is targeting a 2021 US launch for the test, which uses a pair of protein markers to diagnose stroke and allow treatment to begin more quickly.
The firms said they are collaborating to facilitate genetic testing to support early diagnosis of GM1, a rare monogenic recessive lysosomal storage disease.
The company plans to launch a test that leverages unfolded p53 as a biomarker for detection by mass spectrometry in a US-based CLIA-certified lab late next year.
